ClearPoint Neuro (NASDAQ:CLPT) Downgraded by Wall Street Zen to Sell

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Saturday.

Separately, Stifel Nicolaus boosted their target price on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a "buy" rating in a report on Tuesday, April 1st.

ClearPoint Neuro Trading Down 4.7%

Shares of ClearPoint Neuro stock opened at $11.40 on Friday. The company's fifty day simple moving average is $12.34 and its two-hundred day simple moving average is $13.93. The company has a market cap of $319.09 million, a P/E ratio of -15.00 and a beta of 0.92. ClearPoint Neuro has a 12-month low of $6.25 and a 12-month high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 64.51% and a negative return on equity of 78.09%. The business had revenue of $8.49 million for the quarter, compared to the consensus estimate of $8.21 million. Analysts predict that ClearPoint Neuro will post -0.66 EPS for the current fiscal year.

Insider Transactions at ClearPoint Neuro

In related news, CEO Joseph Burnett sold 21,247 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $13.29, for a total value of $282,372.63. Following the transaction, the chief executive officer owned 243,522 shares in the company, valued at $3,236,407.38. The trade was a 8.02% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Timothy T. Richards sold 10,000 shares of the company's stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $13.28, for a total transaction of $132,800.00. Following the completion of the transaction, the director owned 77,381 shares in the company, valued at approximately $1,027,619.68. The trade was a 11.44% decrease in their position. The disclosure for this sale can be found here. Insiders own 6.97% of the company's stock.

Hedge Funds Weigh In On ClearPoint Neuro

A number of hedge funds have recently bought and sold shares of the company. AlphaQuest LLC bought a new position in ClearPoint Neuro during the 4th quarter valued at about $80,000. Virtu Financial LLC bought a new position in ClearPoint Neuro during the 4th quarter valued at about $316,000. LPL Financial LLC lifted its stake in ClearPoint Neuro by 4.5% during the 4th quarter. LPL Financial LLC now owns 40,250 shares of the company's stock valued at $619,000 after acquiring an additional 1,750 shares during the period. Vanguard Group Inc. lifted its stake in ClearPoint Neuro by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 1,248,393 shares of the company's stock valued at $19,200,000 after acquiring an additional 5,400 shares during the period. Finally, Trexquant Investment LP lifted its stake in ClearPoint Neuro by 10.3% during the 4th quarter. Trexquant Investment LP now owns 78,362 shares of the company's stock valued at $1,205,000 after acquiring an additional 7,290 shares during the period. Institutional investors own 30.08% of the company's stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.